Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04480372
Recruitment Status : Recruiting
First Posted : July 21, 2020
Last Update Posted : February 12, 2021
Sponsor:
Information provided by (Responsible Party):
Swiss Group for Clinical Cancer Research

Brief Summary:

A significant number of patients with malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) are not cured with available treatments and will eventually relapse. After relapse treatment options are limited. Preclinical in vitro studies have demonstrated a synergism of immunotherapy with PD(L)1-targeting monoclonal antibodies and gemcitabine and ongoing clinical studies showed encouraging results.

The main objective of this trial is to determine the efficacy of chemotherapy (gemcitabine) combined with immunotherapy (atezolizumab) in patients with progressive NSCLC and MPM.

The trial treatments will be continued for max. 2 years or until discontinuation criteria are met. The follow-up phase will last up to 5 years from treatment start.


Condition or disease Intervention/treatment Phase
Malignant Pleural Mesothelioma Non-small Cell Lung Cancer Drug: Gemcitabine Drug: Atezolizumab Phase 2

Detailed Description:

The trial combines two (Gemcitabine and Atezolizumab). Gemcitabine, alone or in combination regimens is a standard of care for several solid tumors, such as advanced or metastatic NSCLC. It is also used in an off-label setting for pre-treated MPM or naïve MPM in combination with platin-chemotherapy.

Atezolizumab is approved in the United States, European Union and in Switzerland for the treatment of NSCLC, urothelial carcinoma, small cell lung cancer (SCLC) and triple-negative breast cancer (TNBC) patients.

A significant number of patients with malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) are not cured with available treatments and will eventually relapse. After relapse treatment options are limited. Preclinical in vitro studies have demonstrated a synergism of immunotherapy with PD(L)1-targeting monoclonal antibodies and gemcitabine administered in different tumors models and ongoing clinical studies showed encouraging results. This may represent a safe and effective therapy for patients who relapsed or did not respond to standard therapies.

Patients will be treated with gemcitabine (1000 mg/m2 i.v. on day 1 and day 8 of each cycle, (every 3 weeks) and with atezolizumab (1200 mg i.v. on day 1 of each cycle, (every 3 weeks). The trial treatments will be continued for max. 2 years or until discontinuation criteria are met. The follow-up phase will last up to 5 years from treatment start.

The main objective of this trial is to determine the efficacy of chemotherapy (gemcitabine) combined with immunotherapy (atezolizumab) in patients with progressive NSCLC and MPM.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 67 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: A multicenter, single-arm, open label phase II trial with two cohorts.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Overcoming Resistance to Immunotherapy Combining Gemcitabine With Atezolizumab in Advanced NSCLC and Mesothelioma Progressing Under Immune-checkpoint Inhibitors or Gemcitabine. A Multicenter, Single-arm, Open Label Phase II Trial With Two Cohorts
Estimated Study Start Date : April 2021
Estimated Primary Completion Date : April 2025
Estimated Study Completion Date : December 2025


Arm Intervention/treatment
Experimental: NSCLC (cohort 1) and inoperable MPM (cohort 2)

Cohort 1 consists of NSCLC patients. Cohort 2 consists of MPM patients.

Patients will be treated with gemcitabine at the dose of 1000 mg/m2 i.v. on day 1 and day 8 of each cycle (every 3 weeks) and with atezolizumab at the dose of 1200 mg i.v. on day 1 of each cycle (every 3 weeks).

The trial treatments will be continued for max. 2 years or until discontinuation criteria are met (see Ch. 9.3), whichever occurs first. The follow-up phase will last up to 5 years from treatment start.

Drug: Gemcitabine
Gemcitabine is administered at the dose of 1000 mg/m2 intravenously (i.v.) on day 1 and day 8 of each cycle (every 3 weeks).

Drug: Atezolizumab
Atezolizumab is administered at the dose of 1200 mg i.v. on day 1 of each cycle (every 3 weeks).




Primary Outcome Measures :
  1. Primary endpoint for cohort 1: Objective response rate (ORR) according to RECIST 1.1 [ Time Frame: At the date of tumor assessment according to RECIST 1.1, assessed up to 2 years after registration ]

    ORR according to RECIST 1.1 is defined as the proportion of patients, whose best overall response is either complete response (CR) or partial response (PR) achieved during trial treatment until disease progression according to RECIST 1.1.

    Patients with CR or PR as best observed response during trial treatment will be considered as success; otherwise as failures for this endpoint.

    Patients without any tumor assessment or with non-evaluable response (NE) during trial treatment will be considered as failures for this endpoint.


  2. Primary endpoint for cohort 2: ORR according to mRECIST [ Time Frame: At the date of tumor assessment according to mRECIST, assessed up to 2 years after registration ]

    ORR according to mRECIST is defined as the proportion of patients, whose best overall response is either complete response (CR) or partial response (PR) achieved during trial treatment until disease progression according to mRECIST.

    Patients with CR or PR as best observed response during trial treatment will be considered as success; otherwise as failures for this endpoint.

    Patients without any tumor assessment or with non-evaluable response (NE) during trial treatment will be considered as failures for this endpoint.



Secondary Outcome Measures :
  1. For cohort 1 (NSCLC): Duration of response (DoR) according to RECIST 1.1 [ Time Frame: From the time from the first documentation of CR or PR (whichever occurs first) until disease progression according to RECIST 1.1 or death due to any cause, assessed up to 5 years after registration ]

    DoR according to RECIST 1.1 is defined as the time from the first documentation of CR or PR (whichever occurs first) until disease progression according to RECIST 1.1 or death due to any cause.

    Patients not experiencing an event at the time of analysis and those starting a subsequent treatment without an event will be censored at the date of their last available tumor assessment before starting subsequent treatment, if any.

    This endpoint will be calculated for the subgroup of patients achieving CR or PR.


  2. For cohort 1 (NSCLC): Progression-free survival (PFS) according to RECIST 1.1 [ Time Frame: From the date of first dose of atezolizumab/gemcitabine until the date of progressive disease according to RECIST 1.1 or death due to any cause, whichever occurs first, assessed up to 5 years after the first registration ]

    PFS according to RECIST 1.1 is measured as the time from the first dose of atezolizumab/gemcitabine until disease progression according to RECIST 1.1 or death due to any cause.

    Patients not experiencing an event at the time of analysis and those receiving a subsequent treatment without an event will be censored at the date of their last available tumor assessment before starting subsequent treatment, if any.


  3. For cohort 1 (NSCLC): Disease control rate (DCR) at 18 weeks according to RECIST 1.1 [ Time Frame: At the date of tumor assessment according to RECIST 1.1, assessed up to 2 years after registration ]

    DCR at 18 weeks according to RECIST 1.1 is defined as the proportion of patients, whose best overall response is either CR, PR or stable disease maintained for at least 18 weeks (SD≥18weeks) during trial treatment until disease progression according to RECIST 1.1.

    Patients with CR, PR, SD≥18weeks as best observed response during the trial treatment until disease progression according to RECIST 1.1 will be considered as success; otherwise as failures for this endpoint.

    Patients without any tumor assessment or with non-evaluable response (NE) during trial treatment will be considered as failures for this endpoint.


  4. For cohort 2 (MPM): ORR according to mRECIST 1.1 [ Time Frame: At the date of tumor assessment according to mRECIST 1.1, assessed up to 2 years after registration ]

    ORR according to mRECIST 1.1 is defined as the proportion of patients whose best overall response is either CR or PR achieved during trial treatment until disease progression according to mRECIST 1.1.

    Patients with CR or PR as best observed response will be considered as success; otherwise as failures for this endpoint.

    Patients without any tumor assessment or with non-evaluable response (NE) during trial treatment will be considered as failures for this endpoint.


  5. For cohort 2 (MPM): DoR according to mRECIST 1.1 [ Time Frame: From the time from the first documentation of CR or PR (whichever occurs first) until disease progression according to mRECIST 1.1 or death due to any cause, assessed up to 5 years after registration ]

    DoR according to mRECIST 1.1 is defined as the time from the first documentation of CR or PR (whichever occurs first) until disease progression according to mRECIST 1.1 or death due to any cause, whichever occurs first.

    Patients not experiencing an event at the time of analysis and those starting a subsequent treatment without an event will be censored at the date of their last available tumor assessment before starting subsequent treatment, if any.

    This endpoint will be calculated for the subgroup of patients achieving CR or PR.


  6. For cohort 2 (MPM): PFS according to mRECIST 1.1 [ Time Frame: From the date of first dose of atezolizumab/gemcitabine until the date of progressive disease according to mRECIST 1.1 or death due to any cause, whichever occurs first, assessed up to 5 years after registration ]

    PFS is defined as the time from the first dose of atezolizumab/gemcitabine until disease progression according to mRECIST 1.1 or death due to any cause.

    Patients not experiencing an event at the time of analysis and those receiving a subsequent treatment without an event will be censored at the date of their last available tumor assessment before starting subsequent treatment, if any.


  7. For cohort 2 (MPM): DCR at 18 weeks according to mRECIST 1.1 [ Time Frame: At the date of tumor assessment according to mRECIST 1.1, assessed up to 2 years after registration ]

    DCR at 18 weeks according to mRECIST 1.1 is defined as the proportion of patients whose confirmed best overall response is either CR, PR or stable disease maintained for at least 18 weeks (SD≥18weeks) during trial treatment until disease progression according to mRECIST 1.1.

    Patients with CR, PR, SD18weeks as best observed response will be considered as success; otherwise as failures for this endpoint.

    Patients without any tumor assessment or with non-evaluable response (NE) during trial treatment will be considered as failures for this endpoint.


  8. For cohort 1 and cohort 2: Objective response rate according to iRECIST (iORR) [ Time Frame: At the date of tumor assessment according to iRECIST, assessed up to 2 years after registration ]

    iORR is defined as the proportion of patients whose best overall response is either (CR/iCR) or (PR/iPR) according to RECIST 1.1, modified RECIST 1.1 or iRECIST achieved during trial treatment until disease progression according to iRECIST.

    Patients with CR/iCR or PR/iPR as best observed response during trial treatment until disease progression according to iRECIST will be considered as a success; otherwise as failures for this endpoint.

    Patients without any tumor assessment or with non-evaluable response (NE) during trial treatment will be considered as failures for this endpoint.


  9. For cohort 1 and cohort 2: DoR according to iRECIST (iDoR) [ Time Frame: From the time of documentation of CR or PR (whichever occurs first) until disease progression according to iRECIST or death due to any cause, assessed up to 5 years after registration ]

    iDoR is defined as the time from the first documentation of CR/iCR or PR/iPR (whichever occurs first) according to RECIST 1.1, modified RECIST 1.1 or iRECIST achieved during trial treatment until disease progression according to iRECIST or death due to any cause.

    Patients not experiencing an event at the time of analysis and those starting a subsequent treatment without an event will be censored at the date of their last available tumor assessment before starting subsequent treatment, if any.

    This endpoint will be calculated for the subgroup of patients achieving CR/iCR or PR/iPR.


  10. For cohort 1 and cohort 2: PFS according to iRECIST (iPFS) [ Time Frame: From the date of first dose of treatment until the date of progressive disease according to iRECIST or death due to any cause, whichever occurs first, assessed up to 5 years after registration ]

    iPFS is defined as the time from the first dose of atezolizumab/gemcitabine until disease progression according to iRECIST or death due to any cause.

    Patients not experiencing an event at the time of analysis and those receiving a subsequent treatment without an event will be censored at the date of their last available tumor assessment before starting subsequent treatment, if any.


  11. For cohort 1 and cohort 2: Overall Survival (OS) [ Time Frame: From the date of from the first dose of atezolizumab/gemcitabine until the date of death from any cause, assessed up to 5 years after registration ]
    OS is defined as the time from the first dose of atezolizumab/gemcitabine until death due to any cause. Patients alive or lost to follow-up will be censored at the last date where they will be known to be alive.

  12. For cohort 1 and cohort 2: Adverse events (AEs) will be assessed according to CTCAE v5.0. [ Time Frame: Up to 5 years after registration ]
    AEs will be assessed according to CTCAE v5.0.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent according to Swiss law and ICH/GCP regulations before registration and prior to any trial specific procedures including screening procedures.
  • For Cohort 1 (NSCLC): Patients with histologically- or cytologically- confirmed squamous or non-squamous metastatic NSCLC stage IIIB-IV (based on TNM classification). Patients must have experienced disease recurrence or progression during or after one or more prior immunotherapy or chemo-immunotherapy regimen for metastatic disease.
  • For Cohort 2 (MPM): Patients with histologically confirmed inoperable MPM (with or without metastasis; all histological subtypes are eligible). Participants must have experienced disease recurrence or progression during or after one or more prior systemic therapy regimen for advanced or metastatic disease.
  • Patients with treated and stable CNS metastases are eligible, if:

    • Previous CNS-directed therapy has been completed at least 4 weeks prior to treatment start
    • No evidence of progression after completion of CNS-directed therapy as ascertained by clinical examination and brain imaging (MRI or CT).
  • Patients with known HIV-infection are eligible, if:

    • CD4+ T-cell counts are ≥ 350 cells/ųl
    • No history of AIDS-defining opportunistic infection within past 12 months
    • Patient agrees to concomitant antiretroviral therapy (ART) if not currently on ART, or is on ART for ˃ 4 weeks and has a HIV viral load ˂ 400 copies/ml.
  • Patients with a previously treated malignancy are eligible if this is clinically stable and does not require concurrent tumor-directed treatment.

Exception: patients suffering from prostate cancer under hormonal ablation therapy (hormone sensitive disease) are eligible.

  • Patients with measurable disease according to RECIST 1.1 or mRECIST 1.1.
  • Availability of samples for translational research prior to treatment start. For the tumor samples either archival or freshly prepared biopsy samples (cytology is not allowed) are acceptable. Acceptable samples include core needle biopsies for deep tumor tissue (minimum three cores) or excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous, or mucosal lesions. See Ch. 12 and 17 for further details.
  • Age ≥ 18 years.
  • ECOG performance status 0-2.
  • Adequate bone marrow function: absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelet count ≥ 100 x 109/L, hemoglobin ≥ 90 g/L or ≥ 5.6 mmol/L.
  • Adequate hepatic function: total bilirubin ≤ 1.5 x ULN (except for patients with Gilbert's disease ≤ 3.0 x ULN), AST and ALT ≤ 2.5 x ULN, or ≤ 5 x ULN for patients with hepatic metastasis.
  • Adequate renal function: estimated glomerular filtration rate (eGFR) ≥ 40 ml/min/1.73 m2 (according to the Chronic Kidney Disease Epidemiology Collaboration) abbreviated formula CKD-EPI formula).
  • Women of childbearing potential, including women who had their last menstrual period in the last 2 years, must use highly effective contraception, are not pregnant or lactating and agree not to become pregnant during trial treatment and until 5 months after the last dose of investigational drug. A negative serum or urine pregnancy test before starting of trial treatment is required for all women of childbearing potential.
  • Men agree not to donate sperm or to father a child during trial treatment and until 5 months after the last dose of investigational drug (www.swissmedicinfo.ch).
  • Patients consent to the mandatory translational research projects providing the required samples.

Exclusion criteria

The presence of any one of the following exclusion criteria will lead to exclusion of the participant:

  • Symptomatic brain metastases indicative of active disease (defined as new and/or progressive brain metastases at the time of treatment start [38]) or leptomeningeal disease.
  • Prior treatment with gemcitabine in combination with atezolizumab.
  • NSCLC patients who progressed within the first 8 weeks from start of first line treatment.
  • NSCLC patients with activating EGFR or ALK mutations.
  • Known unstable or unresolved surgical or chemotherapy-related toxicity that would compromise trial treatment' duration.
  • Concomitant or recent treatment (within 30 days prior to trial treatment start) with any other experimental drug (enrollment in another clinical trial).
  • Concomitant use of other anti-cancer drugs or radiotherapy (except for local pain control).
  • Cardiac disease NYHA 2 or greater.
  • Major surgery within 1 month prior to trial treatment start.
  • Known history of any uncontrolled active systemic infection requiring intravenous (i.v.) antimicrobial treatment.
  • Known history of tuberculosis, of primary immunodeficiency, of allogeneic tissue/solid organ transplant, of receipt of live attenuated vaccine within 28 days prior to treatment start.
  • History of interstitial lung disease (ILD) or severe pneumonitis (other than chronic obstructive pulmonary disease -COPD- exacerbation) that have required oral or i.v. steroids, or uncontrolled pleural effusion.
  • Concomitant use of corticosteroids as premedication for chemotherapy.
  • Concomitant or prior use of immunosuppressive medication (such as interferon, methotrexate) within 28 days prior to trial treatment start, with the exceptions of intranasal and inhaled corticosteroids.
  • Any concomitant drugs contraindicated for use with the trial drugs according to the approved product information or to the Investigator' Brochure.
  • Known or suspected hypersensitivity to trial drug(s) or to any component of the trial drug(s).
  • Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04480372


Contacts
Layout table for location contacts
Contact: Zuzanna Maniecka, PhD +41 31 389 91 91 trials@sakk.ch

Locations
Layout table for location information
Switzerland
HFR Fribourg Recruiting
Fribourg, Villars-sur-Glâne, Switzerland, 1752
Contact: Adrienne Bettini, MD    +41 26 426 72 43    adrienne.bettini@h-fr.ch   
Principal Investigator: Adrienne Bettini, MD         
Kantonsspital Aarau Not yet recruiting
Aarau, Switzerland, CH-5001
Contact: Wolf-Dieter Janthur, MD    +41 62 838 55 80    wolf-dieter.janthur@ksa.ch   
Principal Investigator: Wolf-Dieter Janthur, MD         
Kantonsspital Baden Recruiting
Baden, Switzerland, 5404
Contact: Christine Waibel, MD    +41 56 486 27 62    christine.waibel@ksb.ch   
Principal Investigator: Christine Waibel, MD         
Universitaetsspital Basel Recruiting
Basel, Switzerland, 4031
Contact: Sacha Rothschild, MD    +41 (0)61 265 25 25    sacha.rothschild@usb.ch   
Principal Investigator: Sacha Rothschild, MD         
St. Claraspital Not yet recruiting
Basel, Switzerland
Contact: Catherine Schill, MD    +41 61 685 85 85    catherine.schill@claraspital.ch   
Principal Investigator: Catherine Schill, MD         
Inselspital Recruiting
Bern, Switzerland, 3010
Contact: Amina Scherz, MD    +41 31 362 21 11    amina.scherz@insel.ch   
Principal Investigator: Amina Scherz, MD         
Kantonsspital Graubuenden Recruiting
Chur, Switzerland, CH-7000
Contact: Roger von Moos, MD    41-81-256-6111    roger.vonmoos@ksgr.ch   
Principal Investigator: Roger von Moos, MD         
Hôpitaux Universitaires de Genève Recruiting
Genève, Switzerland, 1211
Contact: Alfredo Addeo, MD    +41 79 553 50 35    alfredo.addeo@hcuge.ch   
Principal Investigator: Alfredo Addeo, MD         
Kantonsspital St. Gallen Recruiting
St. Gallen, Switzerland, CH-9007
Contact: Markus Jörger, MD    +41 76 559 10 70    markus.joerger@kssg.ch   
Principal Investigator: Markus Jörger, MD         
Kantonsspital Winterthur Not yet recruiting
Winterthur, Switzerland, CH-8400
Contact: Miklos Pless, Prof.    41-52-266-2552    miklos.pless@ksw.ch   
Principal Investigator: Miklos Pless, Prof.         
Klinik Hirslanden Onkozentrum Zürich Recruiting
Zurich, Switzerland, CH-8032
Contact: Thomas von Briel, MD    +41 (0)44 387 21 11    vonbriel@onkozentrum.ch   
Principal Investigator: Thomas von Briel, MD         
UniversitätsSpital Zürich Recruiting
Zürich, Switzerland, 8091
Contact: Alessandra Curioni Fontecedro, MD    +41 44 255 89 02    alessandra.curioni@usz.ch   
Principal Investigator: Alessandra Curioni Fontecedro, MD         
Sponsors and Collaborators
Swiss Group for Clinical Cancer Research
Investigators
Layout table for investigator information
Study Chair: Alessandra Curioni Fontecedro, MD University of Zurich
Layout table for additonal information
Responsible Party: Swiss Group for Clinical Cancer Research
ClinicalTrials.gov Identifier: NCT04480372    
Other Study ID Numbers: SAKK 17/18
First Posted: July 21, 2020    Key Record Dates
Last Update Posted: February 12, 2021
Last Verified: February 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Swiss Group for Clinical Cancer Research:
non-small cell lung cancer
malignant pleural mesothelioma
Immunotherapy
Gemcitabine
Atezolizumab
phase II trial
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Mesothelioma
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms, Mesothelial
Gemcitabine
Atezolizumab
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs